210 related articles for article (PubMed ID: 35490364)
1. Evaluation of cerebrospinal fluid neurofilament light chain levels in multiple sclerosis and non-demyelinating diseases of the central nervous system: clinical and biochemical perspective.
Arslan B; Ayhan Arslan G; Tuncer A; Karabudak R; Sepici Dinçel A
Bosn J Basic Med Sci; 2022 Sep; 22(5):699-706. PubMed ID: 35490364
[TBL] [Abstract][Full Text] [Related]
2. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa.
Kuhle J; Barro C; Andreasson U; Derfuss T; Lindberg R; Sandelius Å; Liman V; Norgren N; Blennow K; Zetterberg H
Clin Chem Lab Med; 2016 Oct; 54(10):1655-61. PubMed ID: 27071153
[TBL] [Abstract][Full Text] [Related]
3. Quantitation of neurofilament light chain protein in serum and cerebrospinal fluid from patients with multiple sclerosis using the MSD R-PLEX NfL assay.
Ulndreaj A; Sohaei D; Thebault S; Pons-Belda OD; Fernandez-Uriarte A; Campbell C; Cheo D; Stengelin M; Sigal G; Freedman MS; Scarisbrick IA; Prassas I; Diamandis EP
Diagnosis (Berl); 2023 Aug; 10(3):275-280. PubMed ID: 36788117
[TBL] [Abstract][Full Text] [Related]
4. Increased cerebrospinal fluid neurofilament light chain in central nervous system inflammatory demyelinating disease.
Peng L; Bi C; Xia D; Mao L; Qian H
Mult Scler Relat Disord; 2019 May; 30():123-128. PubMed ID: 30771578
[TBL] [Abstract][Full Text] [Related]
5. A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation.
Gaetani L; Höglund K; Parnetti L; Pujol-Calderon F; Becker B; Eusebi P; Sarchielli P; Calabresi P; Di Filippo M; Zetterberg H; Blennow K
Alzheimers Res Ther; 2018 Jan; 10(1):8. PubMed ID: 29370869
[TBL] [Abstract][Full Text] [Related]
6. Neurofilament light chain in a phase 2 clinical trial of ibudilast in progressive multiple sclerosis.
Fox RJ; Raska P; Barro C; Karafa M; Konig V; Bermel RA; Chase M; Coffey CS; Goodman AD; Klawiter EC; Naismith RT; Kuhle J
Mult Scler; 2021 Nov; 27(13):2014-2022. PubMed ID: 33635141
[TBL] [Abstract][Full Text] [Related]
7. A Comparison of Two Analytical Approaches for the Quantification of Neurofilament Light Chain, a Biomarker of Axonal Damage in Multiple Sclerosis.
Pafiti A; Krashias G; Tzartos J; Tzartos S; Stergiou C; Gaglia E; Smoleski I; Christodoulou C; Pantzaris M; Lambrianides A
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445963
[TBL] [Abstract][Full Text] [Related]
8. Establishment of neurofilament light chain Simoa assay in cerebrospinal fluid and blood.
Hendricks R; Baker D; Brumm J; Davancaze T; Harp C; Herman A; Büdingen HV; Townsend M; Fischer SK
Bioanalysis; 2019 Aug; 11(15):1405-1418. PubMed ID: 31401845
[No Abstract] [Full Text] [Related]
9. Neurofilament levels, disease activity and brain volume during follow-up in multiple sclerosis.
Håkansson I; Tisell A; Cassel P; Blennow K; Zetterberg H; Lundberg P; Dahle C; Vrethem M; Ernerudh J
J Neuroinflammation; 2018 Jul; 15(1):209. PubMed ID: 30021640
[TBL] [Abstract][Full Text] [Related]
10. Cerebrospinal fluid neurofilament light chain predicts disease activity after the first demyelinating event suggestive of multiple sclerosis.
Gaetani L; Eusebi P; Mancini A; Gentili L; Borrelli A; Parnetti L; Calabresi P; Sarchielli P; Blennow K; Zetterberg H; Di Filippo M
Mult Scler Relat Disord; 2019 Oct; 35():228-232. PubMed ID: 31404762
[TBL] [Abstract][Full Text] [Related]
11. Ultrasensitive immunoassay allows measurement of serum neurofilament heavy in multiple sclerosis.
Verberk IMW; Koel-Simmelink M; Twaalfhoven H; Vrenken H; Korth C; Killestein J; Teunissen CE; Bridel C
Mult Scler Relat Disord; 2021 May; 50():102840. PubMed ID: 33626430
[TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal fluid neurofilament light chains predicts early disease-activity in Multiple Sclerosis.
Toscano S; Oteri V; Chisari CG; Finocchiaro C; Lo Fermo S; Valentino P; Bertolotto A; Zappia M; Patti F
Mult Scler Relat Disord; 2023 Dec; 80():105131. PubMed ID: 37951096
[TBL] [Abstract][Full Text] [Related]
13. Microstructural and functional brain abnormalities in multiple sclerosis predicted by osteopontin and neurofilament light.
Orsi G; Cseh T; Hayden Z; Perlaki G; Nagy SA; Giyab O; Olsen DA; Madsen JS; Berki T; Illes Z
Mult Scler Relat Disord; 2021 Jun; 51():102923. PubMed ID: 33813096
[TBL] [Abstract][Full Text] [Related]
14. Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment naïve relapsing MS patients.
Sejbaek T; Nielsen HH; Penner N; Plavina T; Mendoza JP; Martin NA; Elkjaer ML; Ravnborg MH; Illes Z
J Neurol Neurosurg Psychiatry; 2019 Dec; 90(12):1324-1330. PubMed ID: 31611264
[TBL] [Abstract][Full Text] [Related]
15. Comparison of plasma and cerebrospinal fluid neurofilament light in a multiple sclerosis trial.
de Flon P; Laurell K; Sundström P; Blennow K; Söderström L; Zetterberg H; Gunnarsson M; Svenningsson A
Acta Neurol Scand; 2019 May; 139(5):462-468. PubMed ID: 30740668
[TBL] [Abstract][Full Text] [Related]
16. Metabolomics detects clinically silent neuroinflammatory lesions earlier than neurofilament-light chain in a focal multiple sclerosis animal model.
Yeo T; Bayuangga H; Augusto-Oliveira M; Sealey M; Claridge TDW; Tanner R; Leppert D; Palace J; Kuhle J; Probert F; Anthony DC
J Neuroinflammation; 2022 Oct; 19(1):252. PubMed ID: 36210459
[TBL] [Abstract][Full Text] [Related]
17. Serum and cerebrospinal neurofilament light chain levels in patients with acquired peripheral neuropathies.
Mariotto S; Farinazzo A; Magliozzi R; Alberti D; Monaco S; Ferrari S
J Peripher Nerv Syst; 2018 Sep; 23(3):174-177. PubMed ID: 29974556
[TBL] [Abstract][Full Text] [Related]
18. Neurofilament light chain as a biomarker of meningoencephalitis of unknown etiology in dogs.
Yun T; Koo Y; Chae Y; Lee D; Kim H; Kim S; Chang D; Na KJ; Yang MP; Kang BT
J Vet Intern Med; 2021 Jul; 35(4):1865-1872. PubMed ID: 34114244
[TBL] [Abstract][Full Text] [Related]
19. Determination of chitinase 3-like 1 in cerebrospinal fluid in multiple sclerosis and other neurological diseases.
Kušnierová P; Zeman D; Hradílek P; Zapletalová O; Stejskal D
PLoS One; 2020; 15(5):e0233519. PubMed ID: 32437412
[TBL] [Abstract][Full Text] [Related]
20. Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study.
Gisslén M; Price RW; Andreasson U; Norgren N; Nilsson S; Hagberg L; Fuchs D; Spudich S; Blennow K; Zetterberg H
EBioMedicine; 2016 Jan; 3():135-140. PubMed ID: 26870824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
